Background and Aim:Direct acting antiviral agents (DAAs) are highly effective and safe treatment in patients with chronic hepatitis C infection (CHC). The aim of this study is to evaluate outcomes of direct acting antiviral drugs for treatment of HCV infection in patients with decompensated liver cirrhosis. Materials and methods: This study included 115 HCV decompensated cirrhotic patients who were treated according to the Egyptian National Treatment Program for Hepatitis C Virus. The patients were divided into 3 groups; Group I,  included 70 patients  received sofosbuvir and daclatasvir for 24 weeks, Group II,  included 18 patients received sofosbuvir, daclatasvir and ribavirin for 12 weeks and control group, included 27 patients refused antiviral therapy.Results: The sustained virologic response (SVR) in the present study was 91% (89.3% in group I and 92.3% in group II) with non-significant difference between both groups. Compared to untreated control group and to baseline parameters, both treated groups showed significant improvement as regarding, liver function, INR, creatinine, Child-Turcott-Pugh score and MELD score12 weeks post-treatment. There was a statistically significant decrease in variceal bleeding, ascites and hepatic encephalopathy in treated group compared to control group with no statistically significant difference recorded between the three studied groups regarding hepatocellular carcinoma, hepatorenal syndrome, spontaneous bacterial peritonitis and  pleural effusion. Conclusions:Treatment of decompensated HCV cirrhotic patients with DAAs had  SVR about 91%. SVR  is associated with improvement in liver function and a significant reduction cirrhotic related complications.